Mara Sansa
Chief Interventional Cardiology - Ospedale Maggiore - Novara - Italy
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mara Sansa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:04 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT00320229 · Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous RegimenAzienda Sanitaria Ospedaliera · terminated · Coronary Disease, Myocardial Infarction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:04 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- 12 citationsRCR 0.3
- Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris.Am J Cardiol · 19917 citationsRCR 0.3
- Similar anti-inflammatory effects of intracoronary and intravenous abciximab during primary percutaneous coronary intervention: a randomized study.J Cardiovasc Med (Hagerstown) · 20155 citationsRCR 0.2